Latest Recruitment News

Flight Centre Travel Group has trimmed its FY26 profit forecast due to Middle East conflict impacts on leisure travel, while launching a fresh $200 million share buy-back reflecting confidence in recovery.

Sierra Nevada Gold (ASX: SNX) reports 60% completion of its Phase 1 drilling at the As Safra copper-gold project in Saudi Arabia, with promising geological signs and ongoing government backing.

EDU Holdings lifted total student enrolments by 32% in Trimester 2 2026, driven by strong growth at its higher education arm Ikon Institute, offsetting softness in its vocational training division.

Neurizon Therapeutics has dosed over 50% of participants in the HEALEY ALS Platform Trial's Regimen I, exceeding recruitment expectations after expanding the cohort from 160 to 240 patients. The accelerated pace puts the company on track for last patient dosing in Q2 2027 and topline results by early Q3 2027.

Vault Minerals has submitted a fully certified Closure Plan Amendment for its Southern Tailings Management Facility, marking a regulatory milestone that supports a planned restart of underground development in Q1 FY27 and gold production in Q1 FY28 at Sugar Zone, Ontario.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Northern Star Resources acknowledges activist investor Elliott's stake and proposals, confirms ongoing CEO recruitment, and highlights progress on key projects while rejecting a sale process.

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Optiscan Imaging has reached the halfway recruitment milestone in its first in-human breast cancer study, advancing its regulatory and commercial ambitions with promising clinical data and expanded trial sites.

Rumble Resources has received the second $5 million milestone payment from Elemental Royalty and satisfied a key condition for its ore toll milling agreement, positioning the Western Queen project for pre-development.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.